CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ: CTNM · HEALTHCARE · BIOTECHNOLOGY
$12.82
+6.48% today
Updated 2026-04-30
Market cap
$463.34M
P/E ratio
—
P/S ratio
11.15x
EPS (TTM)
$-2.17
Dividend yield
—
52W range
$3 – $16
Volume
0.3M
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $50.00M | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | -100.0% | — |
| Cost of revenue | — | $329000.00 | $195000.00 | $258000.00 | $323000.00 |
| Gross profit | — | $-329000.00 | $50.00M | $-258000.00 | $-323000.00 |
| Gross margin | — | — | 100.0% | — | — |
| R&D | $22.36M | $16.89M | $27.60M | $38.16M | $51.52M |
| SG&A | $6.29M | $5.83M | $6.32M | $12.47M | $16.54M |
| Operating income | $-28.65M | $-22.72M | $-16.08M | $-50.89M | $-68.06M |
| Operating margin | — | — | -32.2% | — | — |
| EBITDA | $-28.34M | $-23.54M | $23.57M | $-42.00M | $-68.06M |
| EBITDA margin | — | — | 47.1% | — | — |
| EBIT | $-28.66M | $-23.86M | $23.38M | $-42.26M | $-68.38M |
| Interest expense | $332000.00 | $388000.00 | $208000.00 | $0.00 | — |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-29.00M | $-24.25M | $22.72M | $-42.26M | $-59.98M |
| Net income growth (YoY) | — | +16.4% | +193.7% | -286.0% | -41.9% |
| Profit margin | — | — | 45.4% | — | — |